Prizloncabtagene Autoleucel
PreclinicalCell therapy
Johnson & JohnsonPrizloncabtagene Autoleucel is one of 37 biologic programs targeting Lymphoma. It is currently in Preclinical.
2
Indications
6
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PEG-Intron
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma4 trials
Safety and Efficacy1 trial
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Completed·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1·NCT04317885·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prizloncabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company